Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting

Can Granisetron Injection Used as Primary Prophylaxis Improve the Control of Nausea and Vomiting with Low-Emetogenic Chemotherapy?

“…Most of the local general hospitals have been making granisetron the standard pre-medication for chemotherapy for it is considered as the "latest" 5HT-3 antagonist. In fact, most of the previous studies comparing granisetron and ondansetron did not clearly demonstrate superiority of one agent over another (Barrajon, 2000;del Giglio et al, 2000;Jordan et al, 2007). From our observation, granisetron injection appears to be overprescribed for the low emetogenic chemotherapy (LEC) in these settings at the maximum dosage of 3mg (0.04mg/kg).…”

Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy

“…According to the American Society of Clinical Oncology (ASCO) guidelines, an emesis-preventing medication for moderately emetogeneous chemotherapy should include a 5-hydroxytryptamine receptor (5-HTR 3 ) antagonist and dexamethasone, However, in patients receiving a therapy with anthracyclines and cyclophosphamide the combination of dexamethasone, 5-HTR 3 antagonists and neurokinin-1 inhibitor should be given (Kris et al 2006). All used 5-HTR 3 antagonists appear to have similar antiemetic eYcacy (Kris et al 2006;del Giglio et al 2000). Despite improved antiemetic treatment with 5-HTR 3 antagonists, a considerable number of patients still suVer from CINV.…”

Efficacy and Safety of an Increased-dose of Dexamethasone in Patients Receiving Fosaprepitant Chemotherapy in Japan

“…Since a previous report suggested DOI:http://dx.doi.org/10.7314/APJCP.2014.15.1.461 Efficacy and Safety of an Increased-dose that the antiemetic effect of ondansetron and granisetron are equivalent (del Giglio et al, 2000), the specific 5-HT3 antagonist utilized might not have a significant influence on the differences of antiemetic effects between the two regimens used in the present study. However, the 5-HT3 antagonist palonosetron might have improved antiemetic effect, even in the late period, when compared with other 5-HT3 antagonists (Aapro et al, 2006).…”